
==== Front
Front Cell NeurosciFront Cell NeurosciFront. Cell. Neurosci.Frontiers in Cellular Neuroscience1662-5102Frontiers Media S.A. 10.3389/fncel.2019.00353NeuroscienceReviewMast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome Theoharides Theoharis C. 1234*Tsilioni Irene 1Bawazeer Mona 1251Laboratory of Molecular Immunopharmacology and Drug Discovery, Department of Immunology, Tufts University School of Medicine, Boston, MA, United States2Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, MA, United States3Department of Internal Medicine, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, United States4Department of Psychiatry, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, United States5Department of Basic Medical Sciences, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi ArabiaEdited by: Kempuraj Duraisamy, University of Missouri, United States

Reviewed by: Domenico De Berardis, Azienda Usl Teramo, Italy; Mihir Gupta, University of California, San Diego, United States

*Correspondence: Theoharis C. Theoharides, theoharis.theoharides@tufts.eduThis article was submitted to Cellular Neuropathology, a section of the journal Frontiers in Cellular Neuroscience

02 8 2019 2019 13 35320 5 2019 16 7 2019 Copyright © 2019 Theoharides, Tsilioni and Bawazeer.2019Theoharides, Tsilioni and BawazeerThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Fibromyalgia Syndrome (FMS) is a disorder of chronic, generalized muscular pain, accompanied by sleep disturbances, fatigue and cognitive dysfunction. There is no definitive pathogenesis except for altered central pain pathways. We previously reported increased serum levels of the neuropeptides substance P (SP) and its structural analogue hemokinin-1 (HK-1) together with the pro-inflammatory cytokines IL-6 and TNF in FMS patients as compared to sedentary controls. We hypothesize that thalamic mast cells contribute to inflammation and pain, by releasing neuro-sensitizing molecules that include histamine, IL-1β, IL-6 and TNF, as well as calcitonin-gene related peptide (CGRP), HK-1 and SP. These molecules could either stimulate thalamic nociceptive neurons directly, or via stimulation of microglia in the diencephalon. As a result, inhibiting mast cell stimulation could be used as a novel approach for reducing pain and the symptoms of FMS.

mast cellspainneuroinflammationfibromyalgia syndromeproinflammatory cytokines (TNF-alphaIL-1 betaIL-6)
==== Body
Introduction
Fibromyalgia Syndrome is a disorder of chronic generalized muscular pain, stiffness, generalized fatigue, sleep abnormalities, (Clauw et al., 2011; Schmidt-Wilcke and Clauw, 2011; Clauw, 2014) and cognitive problems (Theoharides et al., 2015b; Hauser et al., 2019) assessed by the FSQ (Ferrari and Russell, 2013), which has about 93% sensitivity and 92% specificity (Clauw, 2014). FMS affects about 5% of adults, primarily women 20–60 years of age (Branco et al., 2010) and belongs to a family of overlapping painful conditions (Table 1) known as CSS (Yunus, 2007; Theoharides, 2013). Central sensitization is recognized as the main mechanism involved (Woodman, 2013) and is characterized by allodynia, pain from an otherwise non-painful stimulus, (Russell and Larson, 2009) and hyperalgesia (Staud et al., 2001) due to an exaggerated response to a painful stimulus (Woolf, 2011). The pathogenesis of FMS remains unknown and with no objective diagnostic criteria (McBeth and Mulvey, 2012; Wolfe and Walitt, 2013). FMS patients have reduced tolerance to pain, especially extremes of heat and cold (Desmeules et al., 2003). There is considerable evidence of altered circuity of pain networks and (Jensen et al., 2012; Flodin et al., 2014) abnormal pain processing in FMS (Staud, 2011).

TABLE 1 Pain Syndromes Comorbid with FMS.

• Chronic inflammatory response syndrome (CIRS)
• Functional dyspepsia
• Gulf War Illness (GWI)
• Interstitial cystitis/bladder pain syndrome (IC/BPS)
• Irritable bowel syndrome (IBS) 
• Mast cell mediator disorder (MCMD)
• Mastocytosis
• Migraines
• Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
• Myogenic temporomandibular disorder (TMD)
• Myofacial pain syndrome
• Post-traumatic stress disorder (PTSD)
• Restless leg syndrome 
• Temporomandibular pain syndrome (TMS)
• Tension headache	
The PubMed database was searched between 1960 and 2018 using the terms fatigue, fibromyalgia, hypothalamus, inflammation, mast cells, pain and stress. Only articles in English were included.

Here we discuss how brain mast cell release of neuro-sensitizing mediators in the thalamus leads to focal inflammation and contribute to the pathogenesis of FMS.

Neurohormonal Triggers of Mast Cells Contribute to Focal Inflammation in the Diencephalon
It was recently proposed that FMS may involve localized inflammation in the hypothalamus (Theoharides et al., 2015c). Elevations in pro-inflammatory chemokines/cytokines could negatively impact symptoms (Bazzichi et al., 2007; Carvalho et al., 2008; Nugraha et al., 2013) leading to sensitization of peripheral and central nociceptors (Uceyler et al., 2011; Behm et al., 2012; Hornig et al., 2015). Increased levels of the pro-inflammatory chemokine IL-8 (CXCL8) have been reported in the serum and CSF in patients with FMS (Ross et al., 2010; Kadetoff et al., 2012; Rodriguez-Pinto et al., 2014). Chemokines facilitate nociception by directly acting on chemokine receptors present along the pain pathway (Abbadie, 2005; Charo and Ransohoff, 2006).

The cytokines TNF and IL-17 greatly contribute to the inflammatory response (Romero-Sanchez et al., 2011; Griffin et al., 2012). Plasma levels of IL-17 were increased and correlated with levels of TNF in patients with FMS (Pernambuco et al., 2013). CSF and serum IL-17 also positively correlated with pain (Meng et al., 2013) and anxiety (Liu et al., 2012). Mast cells, themselves, can secrete IL-17; moreover, IL-6 and TGFβ from mast cells contribute to the development of Th-17 cells (Kenna and Brown, 2013).

Fibromyalgia syndrome worsen by stress, (Geenen et al., 2002) which augments pain responses (Bote et al., 2012, 2013). Plasma concentrations of cortisol are increased in the evening, suggesting disruption of the circadian rhythm (Crofford et al., 2004). Serum levels of CRH, which is secreted under stress, were increased in patients with FMS (Tsilioni et al., 2016). CRH was also increased in the CSF of such patients and correlated with severity of pain (McLean et al., 2006). Physiological stress was reported to be the most common trigger in patients with systemic mastocytosis (SM) (Jennings et al., 2014) who also commonly experience FMS (Theoharides et al., 2015d, 2019). We reported increased levels of CRH in the serum of one patient with indolent systemic mastocytosis (Theoharides et al., 2014). CRH can trigger human mast cells to release VEGF without histamine or tryptase (Cao et al., 2005). CRH also has synergistic action with NT stimulating VEGF release. As a result, there is increased vascular permeability in the skin and the blood-brain barrier (BBB) (Esposito et al., 2002; Donelan et al., 2006; Theoharides and Konstantinidou, 2007). Stress also disrupts the gut-blood barrier (Theoharides et al., 1999; Wallon et al., 2008) allowing for gut microbiome-associated molecules, such as propionate (Minerbi et al., 2019) to enter the brain and contribute to focal inflammation. These results have led to the conclusion that mast cells may serve as “immune gate to the brain” (Theoharides, 1990; Ribatti, 2015).

Levels of the neuropeptide SP (Russell, 1998) and NGF (Giovengo et al., 1999) are elevated in the CSF of FMS patients. NGF has been reported to increase nociception and hyperalgesia (Maren, 2017). The SP receptor NK-1 has been involved in the pathophysiology of pain (Greenwood-Van et al., 2014). We reported increased serum levels of SP, its structural analogue Hemokinin-1 (HK-1) and TNF in patients with FMS (Tsilioni et al., 2016). SP (Theoharides et al., 2010a,b) and NGF (Levi-Montalcini, 1987) can stimulate mast cells. Moreover, SP induced mast cell expression of CRHR-1 (Scholzen et al., 2001). Cerebrovascular mast cells were stimulated by CGRP, (Reynier-Rebuffel et al., 1994; Ottosson and Edvinsson, 1997) which is now well established to participate in the pathophysiology of headaches (Edvinsson, 2018). In addition to neuropeptides, sex hormones can also affect mast cell reactivity. For instance, estradiol augments immune (Kovats, 2015) and allergic (Hox et al., 2015) processes. In particular, we had reported expression of estrogen receptors on rodent mast cells (Pang et al., 1995). We also reported that 17β-estradiol further increased stimulation of mast cells by SP (Theoharides et al., 1993). Such findings may help explain why FMS is more common in women.

In addition to allergic reactions, mast cells contribute to innate immunity, (Galli et al., 2011) autoimmunity (Rottem and Mekori, 2005) and inflammation (Theoharides et al., 2010a).

Thalamic Mast Cells Secrete Neurosensitizing Mediators
Increasing evidence supports the involvement of mast cells in FMS (Lucas et al., 2006; Pollack, 2014) and comorbid disorders (Theoharides, 2013) as well as other inflammatory (Galli et al., 2008; Theoharides et al., 2010a) and painful conditions, (Heron and Dubayle, 2013; Chatterjea and Martinov, 2014) as well as neuroimmune interactions (Skaper et al., 2017) (Figure 1). Chronic urticaria, which involves stimulation of skin mast cells is more common in FMS (Torresani et al., 2009). Moreover, mast cells are significantly increased in the papillary dermis of FMS patients (Blanco et al., 2010). The chemokines monocyte chemoattractant protein-1 (MCP-1/CCL2) and eotaxin (CCL-11) are elevated in plasma of FMS patients (Zhang et al., 2008). MCP-1 is a strong mast cell chemoattractant (Conti et al., 1998) and also triggers mast cells in rodents (Conti and Theoharides, 1994). MCP-1 induced prolonged muscle hyperalgesia in rats via activation of its high-affinity receptor, CC Chemokine receptor 2 (CCR2), on the peripheral nerve terminals (Alvarez et al., 2014). Myoblasts treated with MCP-1 secreted significant amounts of the key pro-inflammatory cytokine IL-1β (Zhang et al., 2008). C-reactive protein (CRP) is now considered a marker of chronic inflammation. CRP may be useful in the diagnostic of FMS (and depression/anxiety that often accompany FMS), even though there is no direct correlation reported (De Berardis et al., 2006, 2017; Orsolini et al., 2018).

FIGURE 1 Diagram depicting the involvement of mast cells in the generation of pain in FMS. Mast cells (violet color) in the thalamus secrete pro-inflammatory and neuro-sensitizing mediators (CRH, histamine, IL-6, HK-1, SP, TNF, Tryptase). These mediators can then activate either microglia in thalamic nuclei or ascending nociceptive tracks creating the sensation of pain. Possible natural molecules to inhibit stimulated mast cells and/or microglia are flavonoids such as luteolin or tetramethoxyluteolin (Methlut).

Mast cells derive from the bone marrow and mature in response to SCF, which acts via the cell surface tyrosine kinase KIT receptor (Galli et al., 2011). Mast cell progenitors then migrate in all tissues. As a result, mast cell mediators can affect all organs and lead to multiple symptoms. Mast cells are found adjacent to blood vessels and nerve endings; in the brain, mast cells are located in the thalamus, hypothalamus and median eminence (Edvinsson et al., 1976; Lambracht-Hall et al., 1990; Theoharides et al., 2015d).

Mast cells are known to be stimulated by IgE, via activation of its unique surface receptors (FcεRI) (Rivera et al., 2008). Mast cells can also be stimulated via TLRs, (Abraham and St John, 2010; Zhang et al., 2010). Stimulated mast cells secrete multiple vasoactive, pro-inflammatory and neuro-sensitizing molecules (Galli and Tsai, 2008; Theoharides et al., 2010a). Stimulation of mast cells can be augmented by the cytokine IL-33, (Fux et al., 2014) which synergizes with SP to induce release of impressive amounts of VEGF, (Theoharides et al., 2010b) TNF (Taracanova et al., 2017) or IL-1β (Taracanova et al., 2018). As a result, mast cells can serve as “sensors of cell danger” (Theoharides, 1996; Enoksson et al., 2011; Theoharides et al., 2015a).

Mast cell secretory granules store many preformed pro-inflammatory and neuro-sensitizing mediators including bradykinin, histamine, TNF and tryptase (Nakae et al., 2005; Olszewski et al., 2007). Mast cells also release de novo synthesized molecules: (a) lipid mediators (leukotrienes, prostaglandins, and PAF), (b) cytokines (IL-6, IL-13, IL-33, TNF) and (c) chemokines (CXCL8, CCL2, CCL5), (Theoharides et al., 2015d; Mukai et al., 2018). Mast cell could often release mediators selectively without histamine or tryptase (Theoharides et al., 2007). Mast cells also release IL-31, which is important in the sensation of itching and pain, in response to IgE and SP, IL-33 and specifically their combination (Petra et al., 2018). We reported that mast cells can release mtDNA, which is mistaken as a pathogen and stimulates inflammatory responses (Zhang B. et al., 2012).

Finally, mast cells can release extracellular vesicles (exosomes) (Skokos et al., 2002, 2003) that could deliver regulatory molecules, including mtDNA and microRNAs (Kawikova and Askenase, 2014). Such microvesicles have been implicated in brain disorders (Tsilioni et al., 2014; Kawikova and Askenase, 2014) and pain disorders (Rafiee et al., 2018; Silva-Freire et al., 2019). We recently reported that extracellular vesicles are increased in the serum of children with ASD, contained mtDNA and stimulated cultured human microglia to secrete the pro-inflammatory molecules IL-1β and CXCL8 (Tsilioni and Theoharides, 2018).

Mast Cell Interactions With Microglia
Mast cells communicate with microglia (Skaper et al., 2012, 2014b). Mediators secreted from mast cells, (Zhang et al., 2016) such as histamine (Dong et al., 2014) and tryptase, (Zhang S. et al., 2012) can activate microglia leading to secretion of the pro-inflammatory cytokines IL-1β, IL-6 and TNF. Microglia can also be activated by CRH secreted from mast cells (Wang et al., 2002; Kempuraj et al., 2004). Stimulation of brain mast cells in mice led to activation of microglia, which was decreased by administration of a mast cell inhibitor (Dong et al., 2017).

Microglia are involved in synapse plasticity, (Shemer et al., 2015; Wu et al., 2015; Reu et al., 2017) but are responsible for innate immunity of the brain (Ransohoff and Brown, 2012; Aguzzi et al., 2013). Microglia contribute to brain inflammation (Hagberg et al., 2012; Aguzzi et al., 2013; Nakagawa and Chiba, 2016) and the pathogenesis of different brain disorders, (Takeda et al., 2014; Reus et al., 2015; Faden et al., 2016; Garden and Campbell, 2016; Groh and Martini, 2017; Koutsouras et al., 2017; Pennisi et al., 2017; Jiang et al., 2018; Thonhoff et al., 2018) especially ASD (Vargas et al., 2005; Morgan et al., 2010; Suzuki et al., 2013; Edmonson et al., 2014; Gupta et al., 2014). Microglia in the thalamus have been discussed in the context of pain, especially maintaining the pain sensation even after the original painful stimulus is not present (Banati, 2002; Hansson, 2010; Saghaei et al., 2013; Blaszczyk et al., 2018).

Conclusion
Mast cells have been implicated in headaches (Theoharides, 1983; Theoharides et al., 2005) and pain (Xanthos et al., 2011; Aich et al., 2015; Gupta and Harvima, 2018). Activation of the mast cell-specific receptor, MRGPRX2, (McNeil et al., 2015) and its mouse analogue, Mrgprb2, mediated inflammatory mechanical and thermal hyperalgesia (Green et al., 2019). Hence, mast cells are key players of neuroendocrine (Theoharides, 2017) and painful disorders (Theoharides et al., 2019).

In this context, inhibitors of mast cells (Harvima et al., 2014) would be useful in the treatment of FMS. Natural molecules could include the flavonoids, luteolin (Kempuraj et al., 2008; Theoharides et al., 2015c; Ashaari et al., 2018) and tetramethoxyluteolin, (Theoharides et al., 2017; Theoharides and Tsilioni, 2018) alone or in combination with other substances selected to reduce stress (Theoharides and Kavalioti, 2018). Other natural molecules could include palmitoylethanolamide, (Schweiger et al., 2019) which apparently inhibits neuro-inflammation (Skaper et al., 2013, 2015) and reduces pain (Skaper et al., 2014a; Impellizzeri et al., 2016).

Future Directions
Research should focus on identifying in serum of patients with FMS novel molecules that are involved in pain transmission such as bradykinin, CGRP and IL-31. Extracellular vesicles should also be isolated from the serum and CSF of FMS patients, their content identified, and their effect investigated on cultured human mast cells and microglia. Such possible interactions would serve as useful in vitro assays for the screening of potential novel treatment agents. Recent reports have also stressed the possible use of the cytokine IL-37, (Mastrangelo et al., 2018) which is known to have anti-inflammatory actions (Cavalli and Dinarello, 2018). It would be important to explore the possible use of IL-37 isoforms in the treatment of FMS.

Author Contributions
TT, IT, and MB participated in searching the literature. TT and IT wrote or contributed to the writing of the manuscript. IT prepared the figure.

Conflict of Interest Statement
TT is the inventor of US patents No. 7,906,153 and No. 8,268,365 for the treatment of neuroinflammatory conditions. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding. Some aspects of our work described were supported in part by the National Institutes of Health (NIH) (Grants NS38326 and AR47652), as well as the Michael and Katherine Johnson Family Fund to TT.

Abbreviations
ACRAmerican College of Rheumatology

ASDautism spectrum disorder

CGRPcalcitonin-gene related peptide

CIRSchronic inflammatory response syndrome

CRHcorticotropin-releasing hormone

CSFcerebrospinal fluid

CSScentral sensitivity syndromes

CXCL8IL-8

FcεRIhigh affinity surface receptors

FMSfibromyalgia syndrome

FSQfibromyalgia survey questionnaire

IBSirritable bowel syndrome

IC/BPSinterstitial cystitis/bladder pain syndrome

IgEimmunoglobulin E

MCP-1/CCL2monocyte chemoattractant protein-1

ME/CFSmyalgic encephalomyelitis/chronic fatigue syndrome

MRGPRX2mas-related G-protein coupled receptor member X2

(mt)DNAmitochondrial

NGFnerve growth factor

PAFplatelet activating factor

PTSDpost-traumatic stress disorder

SCFstem cell factor

SPsubstance P

TLRstoll-like receptors

TMDmyogenic temporomandibular disorder.
==== Refs
References
Abbadie C.   (2005 ). Chemokines, chemokine receptors and pain. 
Trends Immunol. 
26 
529 –534 . 10.1016/j.it.2005.08.001 
16099720 
Abraham S. N. St John A. L.   (2010 ). Mast cell-orchestrated immunity to pathogens. 
Nat. Rev. Immunol. 
10 
440 –452 . 10.1038/nri2782 
20498670 
Aguzzi A. Barres B. A. Bennett M. L.   (2013 ). Microglia: scapegoat, saboteur, or something else? 
Science 
339 
156 –161 . 10.1126/science.1227901 
23307732 
Aich A. Afrin L. B. Gupta K.   (2015 ). Mast cell-mediated mechanisms of nociception. 
Int. J. Mol. Sci. 
16 
29069 –29092 . 10.3390/ijms161226151 
26690128 
Alvarez P. Green P. G. Levine J. D.   (2014 ). Role for monocyte chemoattractant protein-1 in the induction of chronic muscle pain in the rat. 
Pain 
155 
1161 –1167 . 10.1016/j.pain.2014.03.004 
24637038 
Ashaari Z. Hadjzadeh M. A. Hassanzadeh G. Alizamir T. Yousefi B. Keshavarzi Z.   (2018 ). The flavone luteolin improves central nervous system disorders by different mechanisms: a review. 
J. Mol. Neurosci. 
65 
491 –506 . 10.1007/s12031-018-1094-2 
30083786 
Banati R. B.   (2002 ). Brain plasticity and microglia: is transsynaptic glial activation in the thalamus after limb denervation linked to cortical plasticity and central sensitisation? 
J. Physiol. Paris 
96 
289 –299 . 10.1016/s0928-4257(02)00018-9 
12445908 
Bazzichi L. Rossi A. Massimetti G. Giannaccini G. Giuliano T. De Feo F.   (2007 ). Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. 
Clin. Exp. Rheumatol. 
25 
225 –230 . 17543146 
Behm F. G. Gavin I. M. Karpenko O. Lindgren V. Gaitonde S. Gashkoff P. A.   (2012 ). Unique immunologic patterns in fibromyalgia. 
BMC Clin. Pathol. 
12 :25 . 10.1186/1472-6890-12-25 
23245186 
Blanco I. Beritze N. Arguelles M. Carcaba V. Fernandez F. Janciauskiene S.   (2010 ). Abnormal overexpression of mastocytes in skin biopsies of fibromyalgia patients. 
Clin. Rheumatol. 
29 
1403 –1412 . 10.1007/s10067-010-1474-7 
20428906 
Blaszczyk L. Maitre M. Leste-Lasserre T. Clark S. Cota D. Oliet S. H. R.   (2018 ). Sequential alteration of microglia and astrocytes in the rat thalamus following spinal nerve ligation. 
J. Neuroinflammation 
15 :349 . 10.1186/s12974-018-1378-z 
30572902 
Bote M. E. Garcia J. J. Hinchado M. D. Ortega E.   (2012 ). Inflammatory/stress feedback dysregulation in women with fibromyalgia. 
Neuroimmunomodulation 
19 
343 –351 . 10.1159/000341664 
22986514 
Bote M. E. Garcia J. J. Hinchado M. D. Ortega E.   (2013 ). Fibromyalgia: anti-inflammatory and stress responses after acute moderate exercise. 
PLoS One 
8 :e74524 . 10.1371/journal.pone.0074524 
24023948 
Branco J. C. Bannwarth B. Failde I. Abello C. J. Blotman F. Spaeth M.   (2010 ). Prevalence of fibromyalgia: a survey in five European countries. 
Semin. Arthritis Rheum. 
39 
448 –453 . 10.1016/j.semarthrit.2008.12.003 
19250656 
Cao J. Papadopoulou N. Kempuraj D. Boucher W. S. Sugimoto K. Cetrulo C. L.   (2005 ). Human mast cells express corticotropin-releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor. 
J. Immunol. 
174 
7665 –7675 . 10.4049/jimmunol.174.12.7665 
15944267 
Carvalho L. S. Correa H. Silva G. C. Campos F. S. Baiao F. R. Ribeiro L. S.   (2008 ). May genetic factors in fibromyalgia help to identify patients with differentially altered frequencies of immune cells? 
Clin. Exp. Immunol. 
154 
346 –352 . 10.1111/j.1365-2249.2008.03787.x 
19037919 
Cavalli G. Dinarello C. A.   (2018 ). Suppression of inflammation and acquired immunity by IL-37. 
Immunol. Rev. 
281 
179 –190 . 10.1111/imr.12605 
29247987 
Charo I. F. Ransohoff R. M.   (2006 ). The many roles of chemokines and chemokine receptors in inflammation. 
N. Engl. J. Med. 
354 
610 –621 . 10.1056/nejmra052723 
16467548 
Chatterjea D. Martinov T.   (2014 ). Mast cells: versatile gatekeepers of pain. 
Mol. Immunol. 
63 
38 –44 . 10.1016/j.molimm.2014.03.001 
24666768 
Clauw D. J.   (2014 ). Fibromyalgia: a clinical review. 
JAMA 
311 
1547 –1555 . 10.1001/jama.2014.3266 
24737367 
Clauw D. J. Arnold L. M. McCarberg B. H.   (2011 ). The science of fibromyalgia. 
Mayo Clin. Proc. 
86 
907 –911 . 10.4065/mcp.2011.0206 
21878603 
Conti P. Reale M. Barbacane R. C. Letourneau R. Theoharides T. C.   (1998 ). Intramuscular injection of hrRANTES causes mast cell recruitment and increased transcription of histidine decarboxylase: lack of effects in genetically mast cell-deficient W/Wv mice. 
FASEB J. 
12 
1693 –1700 . 10.1096/fasebj.12.15.1693 
9837859 
Conti P. Theoharides T. C.   (1994 ). Monocyte chemotactic Protein-1 (MCP-1) is active on mast cells and causes clump formation. 
Int. J. Immunopathol. Pharmacol. 
7 
149 –151 . 8550082 
Crofford L. J. Young E. A. Engleberg N. C. Korszun A. Brucksch C. B. McClure L. A.   (2004 ). Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. 
Brain Behav. Immun. 
18 
314 –325 . 10.1016/s0889-1591(04)00021-2 
15157948 
De Berardis D. Campanella D. Gambi F. La R. R. Carano A. Conti C. M.   (2006 ). The role of C-reactive protein in mood disorders. 
Int. J. Immunopathol. Pharmacol. 
19 
721 –725 . 17166394 
De Berardis D. Serroni N. Campanella D. Marini S. Rapini G. Valchera A.   (2017 ). Alexithymia, suicide ideation, C-Reactive Protein, and serum lipid levels among outpatients with generalized anxiety disorder. 
Arch. Suicide Res. 
21 
100 –112 . 10.1080/13811118.2015.1004485 
25856390 
Desmeules J. A. Cedraschi C. Rapiti E. Baumgartner E. Finckh A. Cohen P.   (2003 ). Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. 
Arthritis Rheum. 
48 
1420 –1429 . 10.1002/art.10893 
12746916 
Donelan J. Boucher W. Papadopoulou N. Lytinas M. Papaliodis D. Theoharides T. C.   (2006 ). Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process. 
Proc. Natl. Acad. Sci. U.S.A. 
103 
7759 –7764 . 10.1073/pnas.0602210103 
16682628 
Dong H. Zhang W. Zeng X. Hu G. Zhang H. He S.   (2014 ). Histamine induces upregulated expression of histamine receptors and increases release of inflammatory mediators from microglia1. 
Mol. Neurobiol. 
49 
1487 –1500 . 10.1007/s12035-014-8697-6 
24752587 
Dong H. Zhang X. Wang Y. Zhou X. Qian Y. Zhang S.   (2017 ). Suppression of brain mast cells degranulation inhibits microglial activation and central nervous system inflammation. 
Mol. Neurobiol. 
54 
997 –1007 . 10.1007/s12035-016-9720-x 
26797518 
Edmonson C. Ziats M. N. Rennert O. M.   (2014 ). Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. 
Mol. Autism 
5 :3 . 10.1186/2040-2392-5-3 
24410870 
Edvinsson L.   (2018 ). The CGRP pathway in migraine as a viable target for therapies. 
Headache 
58 (Suppl. 1 ), 33 –47 . 10.1111/head.13305 
29697153 
Edvinsson L. Owman C. Sjöberg N. O.   (1976 ). Autonomic nerves, mast cells and amine receptors in human brain vessels. A histochemical and pharmacological study. 
Brain Res. 
115 
377 –393 . 10.1016/0006-8993(76)90356-5 
184880 
Enoksson M. Lyberg K. Moller-Westerberg C. Fallon P. G. Nilsson G. Lunderius-Andersson C.   (2011 ). Mast cells as sensors of cell injury through IL-33 recognition. 
J. Immunol. 
186 
2523 –2528 . 10.4049/jimmunol.1003383 
21239713 
Esposito P. Chandler N. Kandere-Grzybowska K. Basu S. Jacobson S. Connolly R.   (2002 ). Corticotropin-releasing hormone (CRH) and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. 
J. Pharmacol. Exp. Ther. 
303 
1061 –1066 . 10.1124/jpet.102.038497 
12438528 
Faden A. I. Wu J. Stoica B. A. Loane D. J.   (2016 ). Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury. 
Br. J. Pharmacol. 
173 
681 –691 . 10.1111/bph.13179 
25939377 
Ferrari R. Russell A. S.   (2013 ). A questionnaire using the modified 2010 American College of rheumatology criteria for fibromyalgia: specificity and sensitivity in clinical practice. 
J. Rheumatol. 
40 
1590 –1595 . 10.3899/jrheum.130367 
23818707 
Flodin P. D. Martinsen S. Lofgren M. Bileviciute-Ljungar I. Kosek E. Fransson P.   (2014 ). Fibromyalgia is associated with decreased connectivity between pain- and sensorimotor brain areas. 
Brain Connect. 
4 
587 –594 . 10.1089/brain.2014.0274 
24998297 
Fux M. Pecaric-Petkovic T. Odermatt A. Hausmann O. V. Lorentz A. Bischoff S. C.   (2014 ). IL-33 is a mediator rather than a trigger of the acute allergic response in humans. 
Allergy 
69 
216 –222 . 10.1111/all.12309 
24205920 
Galli S. J. Borregaard N. Wynn T. A.   (2011 ). Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. 
Nat. Immunol. 
12 
1035 –1044 . 10.1038/ni.2109 
22012443 
Galli S. J. Tsai M.   (2008 ). Mast cells: versatile regulators of inflammation, tissue remodeling, host defense and homeostasis. 
J. Dermatol. Sci. 
49 
7 –19 . 10.1016/j.jdermsci.2007.09.009 
18024086 
Galli S. J. Tsai M. Piliponsky A. M.   (2008 ). The development of allergic inflammation. 
Nature 
454 
445 –454 . 10.1038/nature07204 
18650915 
Garden G. A. Campbell B. M.   (2016 ). Glial biomarkers in human central nervous system disease. 
Glia 
64 
1755 –1771 . 10.1002/glia.22998 
27228454 
Geenen R. Jacobs J. W. Bijlsma J. W.   (2002 ). Evaluation and management of endocrine dysfunction in fibromyalgia. 
Rheum. Dis. Clin. North Am. 
28 
389 –404 . 10.1016/s0889-857x(01)00009-6 
12122926 
Giovengo S. L. Russell I. J. Larson A. A.   (1999 ). Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. 
J. Rheumatol. 
26 
1564 –1569 . 10405946 
Green D. P. Limjunyawong N. Gour N. Pundir P. Dong X.   (2019 ). A Mast-Cell-Specific receptor mediates neurogenic inflammation and pain. 
Neuron 
101 
412 –420 . 10.1016/j.neuron.2019.01.012 
30686732 
Greenwood-Van M. B. Mohammadi E. Tyler K. Pietra C. Bee L. A. Dickenson A.   (2014 ). Synergistic effect of 5-hydroxytryptamine 3 and neurokinin 1 receptor antagonism in rodent models of somatic and visceral pain. 
J. Pharmacol. Exp. Ther. 
351 
146 –152 . 10.1124/jpet.114.216028 
25077526 
Griffin G. K. Newton G. Tarrio M. L. Bu D. X. Maganto-Garcia E. Azcutia V.   (2012 ). IL-17 and TNF-alpha sustain neutrophil recruitment during inflammation through synergistic effects on endothelial activation. 
J. Immunol. 
188 
6287 –6299 . 10.4049/jimmunol.1200385 
22566565 
Groh J. Martini R.   (2017 ). Neuroinflammation as modifier of genetically caused neurological disorders of the central nervous system: understanding pathogenesis and chances for treatment. 
Glia 
65 
1407 –1422 . 10.1002/glia.23162 
28568966 
Gupta K. Harvima I. T.   (2018 ). Mast cell-neural interactions contribute to pain and itch. 
Immunol. Rev. 
282 
168 –187 . 10.1111/imr.12622 
29431216 
Gupta S. Ellis S. E. Ashar F. N. Moes A. Bader J. S. Zhan J.   (2014 ). Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. 
Nat. Commun. 
5 :5748 . 10.1038/ncomms6748 
25494366 
Hagberg H. Gressens P. Mallard C.   (2012 ). Inflammation during fetal and neonatal life: implications for neurologic and neuropsychiatric disease in children and adults. 
Ann. Neurol. 
71 
444 –457 . 10.1002/ana.22620 
22334391 
Hansson E.   (2010 ). Long-term pain, neuroinflammation and glial activation. 
Scand. J. Pain 
1 
67 –72 . 10.1016/j.sjpain.2010.01.002 
29913949 
Harvima I. T. Levi-Schaffer F. Draber P. Friedman S. Polakovicova I. Gibbs B. F.   (2014 ). Molecular targets on mast cells and basophils for novel therapies. 
J. Allergy Clin. Immunol. 
134 
530 –544 . 10.1016/j.jaci.2014.03.007 
24767877 
Hauser W. Sarzi-Puttini P. Fitzcharles M. A.   (2019 ). Fibromyalgia syndrome: under-, over- and misdiagnosis. 
Clin. Exp. Rheumatol. 
37 (Suppl. 116 ), 90 –97 . 30747096 
Heron A. Dubayle D.   (2013 ). A focus on mast cells and pain. 
J. Neuroimmunol. 
264 
1 –7 . 10.1016/j.jneuroim.2013.09.018 
24125568 
Hornig M. Montoya J. G. Klimas N. G. Levine S. Felsenstein D. Bateman L.   (2015 ). Distinct plasma immune signatures in ME/CFS are present early in the course of illness. 
Sci. Adv. 
1 :e1400121 . 10.1126/sciadv.1400121 
26079000 
Hox V. Desai A. Bandara G. Gilfillan A. M. Metcalfe D. D. Olivera A.   (2015 ). Estrogen increases the severity of anaphylaxis in female mice through enhanced endothelial nitric oxide synthase expression and nitric oxide production. 
J. Allergy Clin. Immunol. 
135 
729 –736 . 10.1016/j.jaci.2014.11.003 
25553642 
Impellizzeri D. Di P. R. Cordaro M. Gugliandolo E. Casili G. Morittu V. M.   (2016 ). Adelmidrol, a palmitoylethanolamide analogue, as a new pharmacological treatment for the management of acute and chronic inflammation. 
Biochem. Pharmacol. 
119 
27 –41 . 10.1016/j.bcp.2016.09.001 
27599446 
Jennings S. Russell N. Jennings B. Slee V. Sterling L. Castells M.   (2014 ). The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. 
J. Allergy Clin. Immunol. Pract. 
2 
70 –76 . 10.1016/j.jaip.2013.09.004 
24565772 
Jensen K. B. Loitoile R. Kosek E. Petzke F. Carville S. Fransson P.   (2012 ). Patients with fibromyalgia display less functional connectivity in the brain’s pain inhibitory network. 
Mol. Pain 
8 :32 . 10.1186/1744-8069-8-32 
22537768 
Jiang N. M. Cowan M. Moonah S. N. Petri W. A. Jr.  (2018 ). The impact of systemic inflammation on neurodevelopment. 
Trends Mol. Med. 
24 
794 –804 . 10.1016/j.molmed.2018.06.008 
30006148 
Kadetoff D. Lampa J. Westman M. Andersson M. Kosek E.   (2012 ). Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. 
J. Neuroimmunol. 
242 
33 –38 . 10.1016/j.jneuroim.2011.10.013 
22126705 
Kawikova I. Askenase P. W.   (2014 ). Diagnostic and therapeutic potentials of exosomes in CNS diseases. 
Brain Res. 
1617 
63 –71 . 10.1016/j.brainres.2014.09.070 
25304360 
Kempuraj D. Papadopoulou N. G. Lytinas M. Huang M. Kandere-Grzybowska K. Madhappan B.   (2004 ). Corticotropin-releasing hormone and its structurally related urocortin are synthesized and secreted by human mast cells. 
Endocrinology 
145 
43 –48 . 10.1210/en.2003-0805 
14576187 
Kempuraj D. Tagen M. Iliopoulou B. P. Clemons A. Vasiadi M. Boucher W.   (2008 ). Luteolin inhibits myelin basic protein-induced human mast cell activation and mast cell dependent stimulation of Jurkat T cells. 
Br. J. Pharmacol. 
155 
1076 –1084 . 10.1038/bjp.2008.356 
18806808 
Kenna T. J. Brown M. A.   (2013 ). The role of IL-17-secreting mast cells in inflammatory joint disease. 
Nat. Rev. Rheumatol. 
9 
375 –379 . 10.1038/nrrheum.2012.205 
23229447 
Koutsouras G. W. Ramos R. L. Martinez L. R.   (2017 ). Role of microglia in fungal infections of the central nervous system. 
Virulence 
8 
705 –718 . 10.1080/21505594.2016.1261789 
27858519 
Kovats S.   (2015 ). Estrogen receptors regulate innate immune cells and signaling pathways. 
Cell Immunol. 
294 
63 –69 . 10.1016/j.cellimm.2015.01.018 
25682174 
Lambracht-Hall M. Dimitriadou V. Theoharides T. C.   (1990 ). Migration of mast cells in the developing rat brain. 
Dev. Brain Res. 
56 
151 –159 . 10.1016/0165-3806(90)90077-c 
2261679 
Levi-Montalcini R.   (1987 ). The nerve growth factor 35 years later. 
Science 
237 
1154 –1162 . 10.1126/science.3306916 
3306916 
Liu Y. Ho R. C. Mak A.   (2012 ). The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. 
Int. J. Rheum. Dis. 
15 
183 –187 . 10.1111/j.1756-185X.2011.01673.x 
22462422 
Lucas H. J. Brauch C. M. Settas L. Theoharides T. C.   (2006 ). Fibromyalgia–new concepts of pathogenesis and treatment. 
Int. J. Immunopathol. Pharmacol. 
19 
5 –10 . 16569342 
Maren S.   (2017 ). Synapse-Specific encoding of fear memory in the amygdala. 
Neuron 
95 
988 –990 . 10.1016/j.neuron.2017.08.020 
28858626 
Mastrangelo F. Frydas I. Ronconi G. Kritas S. K. Tettamanti L. Caraffa A.   (2018 ). Low-grade chronic inflammation mediated by mast cells in fibromyalgia: role of IL-37. 
J. Biol. Regul. Homeost Agents 
32 
195 –198 . 29684996 
McBeth J. Mulvey M. R.   (2012 ). Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria. 
Nat. Rev. Rheumatol. 
8 
108 –116 . 10.1038/nrrheum.2011.216 
22270077 
McLean S. A. Williams D. A. Stein P. K. Harris R. E. Lyden A. K. Whalen G.   (2006 ). Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. 
Neuropsychopharmacology 
31 
2776 –2782 . 10.1038/sj.npp.1301200 
16936702 
McNeil B. D. Pundir P. Meeker S. Han L. Undem B. J. Kulka M.   (2015 ). Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. 
Nature 
519 
237 –241 . 10.1038/nature14022 
25517090 
Meng X. Zhang Y. Lao L. Saito R. Li A. Backman C. M.   (2013 ). Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. 
Pain 
154 
294 –305 . 10.1016/j.pain.2012.10.022 
23246025 
Minerbi A. Gonzalez E. Brereton N. J. B. Anjarkouchian A. Dewar K. Fitzcharles M. A.   (2019 ). Altered microbiome composition in individuals with fibromyalgia. 
Pain 
10.1097/j.pain.0000000000001640 
[Epub ahead of print] . 31219947 
Morgan J. T. Chana G. Pardo C. A. Achim C. Semendeferi K. Buckwalter J.   (2010 ). Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. 
Biol. Psychiatry 
68 
368 –376 . 10.1016/j.biopsych.2010.05.024 
20674603 
Mukai K. Tsai M. Saito H. Galli S. J.   (2018 ). Mast cells as sources of cytokines, chemokines, and growth factors. 
Immunol. Rev. 
282 
121 –150 . 10.1111/imr.12634 
29431212 
Nakae S. Suto H. Kakurai M. Sedgwick J. D. Tsai M. Galli S. J.   (2005 ). Mast cells enhance T cell activation: importance of mast cell-derived TNF. 
Proc. Natl. Acad. Sci. U.S.A. 
102 
6467 –6472 . 10.1073/pnas.0501912102 
15840716 
Nakagawa Y. Chiba K.   (2016 ). Involvement of neuroinflammation during brain development in social cognitive deficits in autism spectrum disorder and schizophrenia. 
J. Pharmacol. Exp. Ther. 
358 
504 –515 . 10.1124/jpet.116.234476 
27384073 
Nugraha B. Korallus C. Kielstein H. Gutenbrunner C.   (2013 ). CD3+CD56+natural killer T cells in fibromyalgia syndrome patients: association with the intensity of depression. 
Clin. Exp. Rheumatol. 
31 
S9 –S15 . 23557873 
Olszewski M. B. Groot A. J. Dastych J. Knol E. F.   (2007 ). TNF trafficking to human mast cell granules: mature chain-dependent endocytosis. 
J. Immunol. 
178 
5701 –5709 . 10.4049/jimmunol.178.9.5701 
17442953 
Orsolini L. Sarchione F. Vellante F. Fornaro M. Matarazzo I. Martinotti G.   (2018 ). Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. 
Curr. Neuropharmacol. 
16 
583 –606 . 10.2174/1570159X16666180119144538 
29357805 
Ottosson A. Edvinsson L.   (1997 ). Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. 
Cephalalgia 
17 
166 –174 . 10.1046/j.1468-2982.1997.1703166.x 
9170339 
Pang X. Cotreau-Bibbo M. M. Sant G. R. Theoharides T. C.   (1995 ). Bladder mast cell expression of high affinity estrogen receptors in patients with interstitial cystitis. 
Br. J. Urol. 
75 
154 –161 . 10.1111/j.1464-410x.1995.tb07303.x 
7850318 
Pennisi M. Crupi R. Di P. R. Ontario M. L. Bella R. Calabrese E. J.   (2017 ). Inflammasomes, hormesis, and antioxidants in neuroinflammation: role of NRLP3 in Alzheimer disease. 
J. Neurosci. Res. 
95 
1360 –1372 . 10.1002/jnr.23986 
27862176 
Pernambuco A. P. Schetino L. P. Alvim C. C. Murad C. M. Viana R. S. Carvalho L. S.   (2013 ). Increased levels of IL-17A in patients with fibromyalgia. 
Clin. Exp. Rheumatol. 
31 
S60 –S63 . 24021410 
Petra A. I. Tsilioni I. Taracanova A. Katsarou-Katsari A. Theoharides T. C.   (2018 ). Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. 
Allergy Asthma Proc. 
39 
153 –160 . 10.2500/aap.2018.38.4105 
29490771 
Pollack S.   (2014 ). Mast cells in fibromyalgia. 
Clin. Exp. Rheumatol. 
33(1 Suppl. 88) :S140 .
Rafiee Z. A. Falahatian M. Alsahebfosoul F.   (2018 ). Serum levels of histamine and diamine oxidase in multiple sclerosis. 
Am. J. Clin. Exp. Immunol. 
7 
100 –105 . 30697467 
Ransohoff R. M. Brown M. A.   (2012 ). Innate immunity in the central nervous system. 
J. Clin. Invest. 
122 
1164 –1171 . 10.1172/JCI58644 
22466658 
Reu P. Khosravi A. Bernard S. Mold J. E. Salehpour M. Alkass K.   (2017 ). The lifespan and turnover of microglia in the human brain. 
Cell Rep. 
20 
779 –784 . 10.1016/j.celrep.2017.07.004 
28746864 
Reus G. Z. Fries G. R. Stertz L. Badawy M. Passos I. C. Barichello T.   (2015 ). The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. 
Neuroscience 
300 
141 –154 . 10.1016/j.neuroscience.2015.05.018 
25981208 
Reynier-Rebuffel A.-M. Mathiau P. Callebert J. Dimitriadou V. Farjaudon N. Kacem K.   (1994 ). Substance P, calcitonin gene-related peptide, and capsaicin release serotonin from cerebrovascular mast cells. 
Am. J. Physiol. Regul. Integr. Comp. Physiol. 
267 
R1421 –R1429 . 7526717 
Ribatti D.   (2015 ). The crucial role of mast cells in blood-brain barrier alterations. 
Exp. Cell Res. 
338 
119 –125 . 10.1016/j.yexcr.2015.05.013 
26004870 
Rivera J. Fierro N. A. Olivera A. Suzuki R.   (2008 ). New insights on mast cell activation via the high affinity receptor for IgE. 
Adv. Immunol. 
98 
85 –120 . 10.1016/S0065-2776(08)00403-3 
18772004 
Rodriguez-Pinto I. Agmon-Levin N. Howard A. Shoenfeld Y.   (2014 ). Fibromyalgia and cytokines. 
Immunol. Lett. 
161 
200 –203 . 10.1016/j.imlet.2014.01.009 
24462815 
Romero-Sanchez C. Jaimes D. A. Londono J. De Avila J. Castellanos J. E. Bello J. M.   (2011 ). Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis. 
Clin. Exp. Rheumatol. 
29 
828 –834 . 22041179 
Ross R. L. Jones K. D. Bennett R. M. Ward R. L. Druker B. J. Wood L. J.   (2010 ). Preliminary evidence of increased pain and elevated cytokines in fibromyalgia patients with defective growth hormone response to exercise. 
Open Immunol. J. 
3 
9 –18 . 10.2174/1874226201003010009 
20467575 
Rottem M. Mekori Y. A.   (2005 ). Mast cells and autoimmunity. 
Autoimmun. Rev. 
4 
21 –27 . 10.1016/j.autrev.2004.05.001 
15652775 
Russell I. J.   (1998 ). Advances in fibromyalgia: possible role for central neurochemicals. 
Am. J. Med. Sci. 
315 
377 –384 . 10.1016/s0002-9629(15)40355-6 
9638894 
Russell I. J. Larson A. A.   (2009 ). Neurophysiopathogenesis of fibromyalgia syndrome: a unified hypothesis. 
Rheum. Dis. Clin. North Am. 
35 
421 –435 . 10.1016/j.rdc.2009.06.005 
19647152 
Saghaei E. Abbaszadeh F. Naseri K. Ghorbanpoor S. Afhami M. Haeri A.   (2013 ). Estradiol attenuates spinal cord injury-induced pain by suppressing microglial activation in thalamic VPL nuclei of rats. 
Neurosci. Res. 
75 
316 –323 . 10.1016/j.neures.2013.01.010 
23419864 
Schmidt-Wilcke T. Clauw D. J.   (2011 ). Fibromyalgia: from pathophysiology to therapy. 
Nat. Rev. Rheumatol. 
7 
518 –527 . 10.1038/nrrheum.2011.98 
21769128 
Scholzen T. E. Steinhoff M. Bonaccorsi P. Klein R. Amadesi S. Geppetti P.   (2001 ). Neutral endopeptidase terminates substance P-induced inflammation in allergic contact dermatitis. 
J. Immunol. 
166 
1285 –1291 . 10.4049/jimmunol.166.2.1285 
11145711 
Schweiger V. Martini A. Bellamoli P. Donadello K. Schievano C. Del B. G.   (2019 ). Ultramicronized palmitoylethanolamide (um-PEA) as add-on treatment in fibromyalgia syndrome (FMS): retrospective observational study on 407 patients. 
CNS Neurol. Disord. Drug Targets 
10.2174/1871527318666190227205359 
[Epub ahead of print] . 30827269 
Shemer A. Erny D. Jung S. Prinz M.   (2015 ). Microglia plasticity during health and disease: an immunological perspective. 
Trends Immunol. 
36 
614 –624 . 10.1016/j.it.2015.08.003 
26431939 
Silva-Freire N. Mayado A. Teodosio C. Jara-Acevedo M. Varez-Twose I. Matito A.   (2019 ). Bone marrow mast cell antibody-targetable cell surface protein expression profiles in systemic mastocytosis. 
Int. J. Mol. Sci. 
20 :E552 . 10.3390/ijms20030552 
30696068 
Skaper S. D. Facci L. Barbierato M. Zusso M. Bruschetta G. Impellizzeri D.   (2015 ). N-Palmitoylethanolamine and neuroinflammation: a novel therapeutic strategy of resolution. 
Mol. Neurobiol. 
52 
1034 –1042 . 10.1007/s12035-015-9253-8 
26055231 
Skaper S. D. Facci L. Fusco M. la Valle M. F. Zusso M. Costa B.   (2014a ). Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain. 
Inflammopharmacology 
22 
79 –94 . 10.1007/s10787-013-0191-7 
24178954 
Skaper S. D. Facci L. Giusti P.   (2014b ). Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. 
CNS Neurol. Disord. Drug Targets 
13 
1654 –1666 . 10.2174/1871527313666141130224206 25470401 
Skaper S. D. Facci L. Giusti P.   (2013 ). Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. 
Mol. Neurobiol. 
48 
340 –352 . 10.1007/s12035-013-8487-6 
23813098 
Skaper S. D. Facci L. Zusso M. Giusti P.   (2017 ). Neuroinflammation, mast cells, and glia: dangerous liaisons. 
Neuroscientist 
23 
478 –498 . 10.1177/1073858416687249 
29283023 
Skaper S. D. Giusti P. Facci L.   (2012 ). Microglia and mast cells: two tracks on the road to neuroinflammation. 
FASEB J. 
26 
3103 –3117 . 10.1096/fj.11-197194 
22516295 
Skokos D. Botros H. G. Demeure C. Morin J. Peronet R. Birkenmeier G.   (2003 ). Mast cell-derived exosomes induce phenotypic and functional maturation of dendritic cells and elicit specific immune responses in vivo. 
J. Immunol. 
170 
3037 –3045 . 10.4049/jimmunol.170.6.3037 
12626558 
Skokos D. Goubran-Botros H. Roa M. Mecheri S.   (2002 ). Immunoregulatory properties of mast cell-derived exosomes. 
Mol. Immunol. 
38 
1359 –1362 . 10.1016/s0161-5890(02)00088-3 
12217408 
Staud R.   (2011 ). Brain imaging in fibromyalgia syndrome. 
Clin. Exp. Rheumatol. 
29 
S109 –S117 . 22243558 
Staud R. Vierck C. J. Cannon R. L. Mauderli A. P. Price D. D.   (2001 ). Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. 
Pain 
91 
165 –175 . 10.1016/s0304-3959(00)00432-2 
11240089 
Suzuki K. Sugihara G. Ouchi Y. Nakamura K. Futatsubashi M. Takebayashi K.   (2013 ). Microglial activation in young adults with autism spectrum disorder. 
JAMA Psychiatry 
70 
49 –58 .23404112 
Takeda S. Sato N. Morishita R.   (2014 ). Systemic inflammation, blood-brain barrier vulnerability and cognitive/non-cognitive symptoms in Alzheimer disease: relevance to pathogenesis and therapy. 
Front. Aging Neurosci. 
6 :171 . 10.3389/fnagi.2014.00171 
25120476 
Taracanova A. Alevizos M. Karagkouni A. Weng Z. Norwitz E. Conti P.   (2017 ). SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. 
Proc. Natl. Acad. Sci. U.S.A. 
114 
E4002 –E4009 . 10.1073/pnas.1524845114 
28461492 
Taracanova A. Tsilioni I. Conti P. Norwitz E. R. Leeman S. E. Theoharides T. C.   (2018 ). Substance P and IL-33 administered together stimulate a marked secretion of IL-1beta from human mast cells, inhibited by methoxyluteolin. 
Proc. Natl. Acad. Sci. U.S.A 
115 
E9381 –E9390 . 10.1073/pnas.1810133115 
30232261 
Theoharides T. C.   (1983 ). Mast cells and migraines. 
Perspect. Biol. Med. 
26 
672 –675 . 10.1353/pbm.1983.0028 6353354 
Theoharides T. C.   (1990 ). Mast cells: the immune gate to the brain. 
Life Sci. 
46 
607 –617 . 10.1016/0024-3205(90)90129-f 
2407920 
Theoharides T. C.   (1996 ). Mast cell: a neuroimmunoendocrine master player. 
Int. J. Tissue React. 
18 
1 –21 . 8880375 
Theoharides T. C.   (2013 ). Atopic conditions in search of pathogenesis and therapy. 
Clin. Ther. 
35 
544 –547 . 10.1016/j.clinthera.2013.04.002 
23642292 
Theoharides T. C.   (2017 ). Neuroendocrinology of mast cells: challenges and controversies. 
Exp. Dermatol. 
26 
751 –759 . 10.1111/exd.13288 
28094875 
Theoharides T. C. Alysandratos K. D. Angelidou A. Delivanis D. A. Sismanopoulos N. Zhang B.   (2010a ). Mast cells and inflammation. 
Biochim. Biophys. Acta 
1822 
21 –33 .21185371 
Theoharides T. C. Zhang B. Kempuraj D. Tagen M. Vasiadi M. Angelidou A.   (2010b ). IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. 
Proc. Natl. Acad. Sci. U.S.A. 
107 
4448 –4453 . 10.1073/pnas.1000803107 
20160089 
Theoharides T. C. Dimitriadou V. Letourneau R. J. Rozniecki J. J. Vliagoftis H. Boucher W. S.   (1993 ). Synergistic action of estradiol and myelin basic protein on mast cell secretion and brain demyelination: changes resembling early stages of demyelination. 
Neuroscience 
57 
861 –871 . 10.1016/0306-4522(93)90030-j 
7508580 
Theoharides T. C. Donelan J. Kandere-Grzybowska K. Konstantinidou A.   (2005 ). The role of mast cells in migraine pathophysiology. 
Brain Res. Brain Res. Rev. 
49 
65 –76 . 10.1016/j.brainresrev.2004.11.006 
15960987 
Theoharides T. C. Kavalioti M.   (2018 ). Stress, inflammation and natural treatments. 
J. Biol. Regul. Homeost Agents 
32 
1345 –1347 . 30574737 
Theoharides T. C. Kempuraj D. Tagen M. Conti P. Kalogeromitros D.   (2007 ). Differential release of mast cell mediators and the pathogenesis of inflammation. 
Immunol. Rev. 
217 
65 –78 . 10.1111/j.1600-065x.2007.00519.x 
17498052 
Theoharides T. C. Konstantinidou A.   (2007 ). Corticotropin-releasing hormone and the blood-brain-barrier. 
Front. Biosci. 
12 :1615 –1628 . 10.2741/2174 17127408 
Theoharides T. C. Letourneau R. Patra P. Hesse L. Pang X. Boucher W.   (1999 ). Stress-induced rat intestinal mast cell intragranular activation and inhibitory effect of sulfated proteoglycans. 
Dig. Dis. Sci. 
44 
87S –93S . 10490045 
Theoharides T. C. Petra A. I. Stewart J. M. Tsilioni I. Panagiotidou S. Akin C.   (2014 ). High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. 
J. Allergy Clin. Immunol. 
134 
1197 –1199 . 10.1016/j.jaci.2014.05.023 
24985398 
Theoharides T. C. Petra A. I. Taracanova A. Panagiotidou S. Conti P.   (2015a ). Targeting IL-33 in autoimmunity and inflammation. 
J. Pharmacol. Exp. Ther. 
354 
24 –31 . 10.1124/jpet.114.222505 
25906776 
Theoharides T. C. Stewart J. M. Hatziagelaki E. Kolaitis G.   (2015b ). Brain “fog,” inflammation and obesity: key aspects of neuropsychiatric disorders improved by luteolin. 
Front. Neurosci. 
9 :225 . 10.3389/fnins.2015.00225 
26190965 
Theoharides T. C. Tsilioni I. Arbetman L. Panagiotidou S. Stewart J. M. Gleason R. M.   (2015c ). Fibromyalgia, a syndrome in search of pathogenesis and therapy. 
J. Pharmacol. Exp. Ther. 
355 
255 –263 .26306765 
Theoharides T. C. Valent P. Akin C.   (2015d ). Mast cells, mastocytosis, and related disorders. 
N. Engl. J. Med. 
373 
163 –172 . 10.1056/nejmra1409760 
26154789 
Theoharides T. C. Stewart J. M. Tsilioni I.   (2017 ). Tolerability and benefit of a tetramethoxyluteolin-containing skin lotion. 
Int. J. Immunopathol. Pharmacol. 
30 
146 –151 . 10.1177/0394632017707610 
28480804 
Theoharides T. C. Tsilioni I.   (2018 ). Tetramethoxyluteolin for the treatment of neurodegenerative diseases. 
Curr. Top. Med. Chem. 
18 
1872 –1882 . 10.2174/1568026617666181119154247 
30451113 
Theoharides T. C. Tsilioni I. Ren H.   (2019 ). Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders? 
Expert. Rev. Clin. Immunol. 
15 
639 –656 . 10.1080/1744666X.2019.1596800 
30884251 
Thonhoff J. R. Simpson E. P. Appel S. H.   (2018 ). Neuroinflammatory mechanisms in amyotrophic lateral sclerosis pathogenesis. 
Curr. Opin. Neurol. 
31 
635 –639 . 10.1097/WCO.0000000000000599 
30048339 
Torresani C. Bellafiore S. De Panfilis G.   (2009 ). Chronic urticaria is usually associated with fibromyalgia syndrome. 
Acta Derm. Venereol. 
89 
389 –392 . 10.2340/00015555-0653 
19688152 
Tsilioni I. Panagiotidou S. Theoharides T. C.   (2014 ). Exosomes in neurologic and psychiatric disorders. 
Clin. Ther. 
36 
882 –888 . 10.1016/j.clinthera.2014.05.005 
24913029 
Tsilioni I. Russell I. J. Stewart J. M. Gleason R. M. Theoharides T. C.   (2016 ). Neuropeptides CRH, SP, HK-1, and inflammatory cytokines IL-6 and TNF are increased in serum of patients with fibromyalgia syndrome, implicating mast cells. 
J. Pharmacol. Exp. Ther. 
356 
664 –672 . 10.1124/jpet.115.230060 
26763911 
Tsilioni I. Theoharides T. C.   (2018 ). Extracellular vesicles are increased in the serum of children with autism spectrum disorder, contain mitochondrial DNA, and stimulate human microglia to secrete IL-1beta. 
J. Neuroinflammation 
15 :239 . 10.1186/s12974-018-1275-5 
30149804 
Uceyler N. Hauser W. Sommer C.   (2011 ). Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. 
BMC Musculoskelet Disord. 
12 :245 . 10.1186/1471-2474-12-245 
22034969 
Vargas D. L. Nascimbene C. Krishnan C. Zimmerman A. W. Pardo C. A.   (2005 ). Neuroglial activation and neuroinflammation in the brain of patients with autism. 
Ann. Neurol. 
57 
67 –81 . 10.1002/ana.20315 
15546155 
Wallon C. Yang P. Keita A. V. Ericson A. C. McKay D. M. Sherman P. M.   (2008 ). Corticotropin releasing hormone (CRH) regulates macromolecular permeability via mast cells in normal human colonic biopsies in vitro. 
Gut 
57 
50 –58 . 10.1136/gut.2006.117549 
17525093 
Wang W. Ji P. Riopelle R. J. Dow K. E.   (2002 ). Functional expression of corticotropin-releasing hormone (CRH) receptor 1 in cultured rat microglia. 
J. Neurochem. 
80 
287 –294 . 10.1046/j.0022-3042.2001.00687.x 
11902119 
Wolfe F. Walitt B.   (2013 ). Culture, science and the changing nature of fibromyalgia. 
Nat. Rev. Rheumatol. 
9 
751 –755 . 10.1038/nrrheum.2013.96 
23820862 
Woodman I.   (2013 ). Fibromyalgia: fibromyalgia-all in the brain? 
Nat. Rev. Rheumatol. 
9 :565 . 10.1038/nrrheum.2013.137 
24045710 
Woolf C. J.   (2011 ). Central sensitization: implications for the diagnosis and treatment of pain. 
Pain 
152 
S2 –S15 . 10.1016/j.pain.2010.09.030 
20961685 
Wu Y. Dissing-Olesen L. MacVicar B. A. Stevens B.   (2015 ). Microglia: dynamic mediators of synapse development and plasticity. 
Trends Immunol. 
36 
605 –613 . 10.1016/j.it.2015.08.008 
26431938 
Xanthos D. N. Gaderer S. Drdla R. Nuro E. Abramova A. Ellmeier W.   (2011 ). Central nervous system mast cells in peripheral inflammatory nociception. 
Mol. Pain 
7 :42 . 10.1186/1744-8069-7-42 
21639869 
Yunus M. B.   (2007 ). Fibromyalgia and overlapping disorders: the unifying concept of central sensitivity syndromes. 
Semin. Arthritis Rheum. 
36 
339 –356 . 10.1016/j.semarthrit.2006.12.009 
17350675 
Zhang B. Asadi S. Weng Z. Sismanopoulos N. Theoharides T. C.   (2012 ). Stimulated human mast cells secrete mitochondrial components that have autocrine and paracrine inflammatory actions. 
PLoS One 
7 :e49767 . 10.1371/journal.pone.0049767 
23284625 
Zhang S. Zeng X. Yang H. Hu G. He S.   (2012 ). Mast cell tryptase induces microglia activation via protease-activated receptor 2 signaling. 
Cell Physiol. Biochem. 
29 
931 –940 . 10.1159/000171029 
22613992 
Zhang Q. Raoof M. Chen Y. Sumi Y. Sursal T. Junger W.   (2010 ). Circulating mitochondrial DAMPs cause inflammatory responses to injury. 
Nature 
464 
104 –107 . 10.1038/nature08780 
20203610 
Zhang X. Wang Y. Dong H. Xu Y. Zhang S.   (2016 ). Induction of microglial activation by mediators released from mast cells. 
Cell Physiol. Biochem. 
38 
1520 –1531 . 10.1159/000443093 
27050634 
Zhang Z. Cherryholmes G. Mao A. Marek C. Longmate J. Kalos M.   (2008 ). High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia. 
Exp. Biol. Med. 
233 
1171 –1180 . 10.3181/0712-RM-328 
18535166

